- CSPC Pharmaceutical reported a net income of 3.78 billion yuan for the first nine months of the year.
- The company’s total revenue reached 22.69 billion yuan over the same period.
- Research and Development (R&D) expenses amounted to 3.88 billion yuan.
- Current analyst ratings for CSPC Pharmaceutical include 23 buy recommendations, 11 hold recommendations, and 1 sell recommendation.
A look at CSPC Pharmaceutical Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group‘s long-term outlook appears to be positive. The company scores high in Dividend and Value, indicating strong performance in these areas. With a solid score in Growth and Resilience as well, CSPC Pharmaceutical Group demonstrates a robust overall outlook. However, its Momentum score is lower, suggesting some room for improvement in this aspect. CSPC Pharmaceutical Group Limited is known for manufacturing and selling a range of pharmaceutical products, including vitamin C, antibiotics, and generic drugs. Additionally, the company is involved in the development of innovative drugs and antibiotics, showcasing a diverse product portfolio.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
